ProMIS Licenses TXP1 Technology to Advance Brain Drug Delivery
Massachusetts, November 17, 2026 ProMIS Neurosciences Inc. (NASDAQ: PMN) has entered into a licensing agreement with Ossianix, Inc. to...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Massachusetts, November 17, 2026 ProMIS Neurosciences Inc. (NASDAQ: PMN) has entered into a licensing agreement with Ossianix, Inc. to...
CAMBRIDGE, Mass., July 28, 2026 ProMIS Neurosciences Inc. announced positive blinded six-month interim safety and biomarker data from the...
CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...
